CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma

Abstract CD96 is a promising candidate for immunotherapy. However, its role and importance in glioma remains unknown. We thus aimed to genetically and clinically characterize CD96 expression in gliomas. For this, we extracted RNA-seq data of 699 glioma samples from the TCGA dataset and validated the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fangkun Liu, Jing Huang, Fengqiong He, Xiaodong Ma, Fan Fan, Ming Meng, Yang Zhuo, Liyang Zhang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/cc2f23111ef7425386ea78d03e4895fc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cc2f23111ef7425386ea78d03e4895fc
record_format	dspace
spelling	oai:doaj.org-article:cc2f23111ef7425386ea78d03e4895fc2021-12-02T18:18:50ZCD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma10.1038/s41598-020-66806-z2045-2322https://doaj.org/article/cc2f23111ef7425386ea78d03e4895fc2020-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-66806-zhttps://doaj.org/toc/2045-2322Abstract CD96 is a promising candidate for immunotherapy. However, its role and importance in glioma remains unknown. We thus aimed to genetically and clinically characterize CD96 expression in gliomas. For this, we extracted RNA-seq data of 699 glioma samples from the TCGA dataset and validated these findings using the CGGA dataset comprising 325 glioma samples. Clinical and isocitrate dehydrogenase (IDH) mutation status were also analyzed. Various packages in R language were mainly used for statistical analysis. CD96 expression was significantly up-regulated in high-grade, IDH-wildtype, and mesenchymal-molecular subtype gliomas based on TCGA data, which was validated using the CGGA dataset. Subsequent gene ontology analysis of both datasets suggested that genes relevant to CD96 are mainly involved in immune functions in glioma as such genes were positively correlated with CD96 expression. To further explore the relationship between CD96 and immune responses, we selected seven immune-related metagenes and found that CD96 expression was positively correlated with HCK, LCK, and MHC II in the CGGA and TCGA cohorts but negatively associated with IgG. Further, Pearson correlation analysis showed that CD96 is associated with TIGIT, CD226, CRTAM, TIM-3, PD-L1, CTLA-4, and STAT3, indicating the additive antitumoral effects of these checkpoint proteins. CD96 was also suggested to play an important role in immune responses and positively collaborate with other checkpoint members. These findings show that CD96 is promising candidate for immunotherapy, and that such agents could complement current immunotherapy strategies for glioma.Fangkun LiuJing HuangFengqiong HeXiaodong MaFan FanMing MengYang ZhuoLiyang ZhangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-10 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Fangkun Liu Jing Huang Fengqiong He Xiaodong Ma Fan Fan Ming Meng Yang Zhuo Liyang Zhang CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma
description	Abstract CD96 is a promising candidate for immunotherapy. However, its role and importance in glioma remains unknown. We thus aimed to genetically and clinically characterize CD96 expression in gliomas. For this, we extracted RNA-seq data of 699 glioma samples from the TCGA dataset and validated these findings using the CGGA dataset comprising 325 glioma samples. Clinical and isocitrate dehydrogenase (IDH) mutation status were also analyzed. Various packages in R language were mainly used for statistical analysis. CD96 expression was significantly up-regulated in high-grade, IDH-wildtype, and mesenchymal-molecular subtype gliomas based on TCGA data, which was validated using the CGGA dataset. Subsequent gene ontology analysis of both datasets suggested that genes relevant to CD96 are mainly involved in immune functions in glioma as such genes were positively correlated with CD96 expression. To further explore the relationship between CD96 and immune responses, we selected seven immune-related metagenes and found that CD96 expression was positively correlated with HCK, LCK, and MHC II in the CGGA and TCGA cohorts but negatively associated with IgG. Further, Pearson correlation analysis showed that CD96 is associated with TIGIT, CD226, CRTAM, TIM-3, PD-L1, CTLA-4, and STAT3, indicating the additive antitumoral effects of these checkpoint proteins. CD96 was also suggested to play an important role in immune responses and positively collaborate with other checkpoint members. These findings show that CD96 is promising candidate for immunotherapy, and that such agents could complement current immunotherapy strategies for glioma.
format	article
author	Fangkun Liu Jing Huang Fengqiong He Xiaodong Ma Fan Fan Ming Meng Yang Zhuo Liyang Zhang
author_facet	Fangkun Liu Jing Huang Fengqiong He Xiaodong Ma Fan Fan Ming Meng Yang Zhuo Liyang Zhang
author_sort	Fangkun Liu
title	CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma
title_short	CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma
title_full	CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma
title_fullStr	CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma
title_full_unstemmed	CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma
title_sort	cd96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/cc2f23111ef7425386ea78d03e4895fc
work_keys_str_mv	AT fangkunliu cd96anewimmunecheckpointcorrelateswithimmuneprofileandclinicaloutcomeofglioma AT jinghuang cd96anewimmunecheckpointcorrelateswithimmuneprofileandclinicaloutcomeofglioma AT fengqionghe cd96anewimmunecheckpointcorrelateswithimmuneprofileandclinicaloutcomeofglioma AT xiaodongma cd96anewimmunecheckpointcorrelateswithimmuneprofileandclinicaloutcomeofglioma AT fanfan cd96anewimmunecheckpointcorrelateswithimmuneprofileandclinicaloutcomeofglioma AT mingmeng cd96anewimmunecheckpointcorrelateswithimmuneprofileandclinicaloutcomeofglioma AT yangzhuo cd96anewimmunecheckpointcorrelateswithimmuneprofileandclinicaloutcomeofglioma AT liyangzhang cd96anewimmunecheckpointcorrelateswithimmuneprofileandclinicaloutcomeofglioma
_version_	1718378182500941824

CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma

Ejemplares similares